<DOC>
	<DOC>NCT00761215</DOC>
	<brief_summary>The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.</brief_summary>
	<brief_title>Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases, Infectious</mesh_term>
	<mesh_term>Skin Diseases, Bacterial</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Diagnosed with complicated skin and skin structure infection with at least 2 signs and symptoms Suspected or confirmed infection due to a grampositive organism Complicated skin and skin structure infection due to gramnegative organisms Complicated skin and skin structure infections requiring more than 7 days of therapy Uncontrolled diabetes Chronic systemic immunosuppressive therapy AIDS with CD4 count &lt; 200 cells/mm3 Uncontrolled hypertension Mild moderate or severe renal failure Severe hepatic disease Neutropenia Use of antidepressants such as SSRIs or MAOIs for 14 days before first dose of study drug Women who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Skin</keyword>
	<keyword>Infection</keyword>
	<keyword>Complicated Skin and Skin Structure Infection</keyword>
</DOC>